Results 191 to 200 of about 2,903,354 (302)

Revisiting suicide prevention in later life: mixed-methods study protocol. [PDF]

BJPsych Open
Troya MI, Corcoran P, Chambers D, Doherty AM, Hennebry D, Kavalidou K, Lonergan C, Lovejoy SA, Mughal F, Norton M, Wallace E, Arensman E.   +11 more
europepmc   +1 more source

Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma

Molecular Oncology, EarlyView.
Bladder tumors with higher pretreatment memory B‐cell infiltration were linked to longer survival after cisplatin chemotherapy, but not carboplatin. These tumors also showed more organized immune structures (tertiary lymphoid structures) and a shared pro‐inflammatory B‐cell‐rich community, suggesting that memory B cells may help identify patients most ...
Konrad Stawiski, Júlia Perera‐Bel, Alejo Rodriguez‐Vida, Nuria Juanpere, Jihyun Lee, Daniel E. Michaud, Jennifer L. Guerriero, Kent W. Mouw, Aristotelis Bamias, Filipe L. F. Carvalho, Joaquim Bellmunt   +10 more
wiley   +1 more source

Barriers and facilitators to telerehabilitation implementation: a mixed-methods study of German physiotherapists. [PDF]

BMC Health Serv Res
Stahn M, Roemhild M, Kopkow C, Rausch AK.   +3 more
europepmc   +1 more source

Liquid biopsy‐based diagnostic evaluation of hypermethylated CpG sites for ovarian cancer diagnosis

Molecular Oncology, EarlyView.
This schematic outlines the workflow from biomarker identification to duplex MethyLight assay validation for epithelial ovarian cancer diagnosis using cfDNA‐based liquid biopsy. Initial screening of hypermethylated CpG candidates (cg02957270, cg10061138 cg00480298, COL2A1) was performed in tissue using ARMS‐PCR, COBRA, qPCR and image analysis. Selected
Deepa Bisht, Sameer Gupta, Amrita Chaurasia, Manisha Sachan   +3 more
wiley   +1 more source

A mixed methods evaluation of mechanisms for facilitation in pediatric primary care. [PDF]

Implement Sci Commun
Boggs JM, Williams N, Waller CR, Pandey M, Johnson C, Ahmedani BK, Pappas C, Bedjeti K, Maye M, Wolk CB, Buttenheim AM, Linn KA, Wright L, Daley MF, Small DS, Beidas RS.   +15 more
europepmc   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Implementation of Emotional Connection Training in Pediatric Primary Care: Mixed Methods Study. [PDF]

JMIR Med Educ
Erickson E, Amati JB, Dumitriu D, Miller-Fitzwater A, Best DL, Preiss D, Uejo E, Brown A, Crotty JE, Gillen L, Grier C, Gustafson KK, Shearman N, Lavallée A, Warmingham J, Arduin E, Shearman N, Young J, Sperling J.   +18 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Determinants of antimicrobial resistance practices in Ethiopia: A One Health mixed-methods study. [PDF]

One Health
Assefa GM, Wgebriel A, Tarekegn M, Gebreselassie G, Shifarraw S, Solomon A, Mihret M, Girmay AH, Belete GA, Abrie W, Majiwa F, Negash K.   +11 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source